Eintrag weiter verarbeiten
Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation
Gespeichert in:
| Zeitschriftentitel: | Scandinavian Journal of Immunology |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Scandinavian Journal of Immunology, 83, 2016, 2, S. 119-127 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| Zusammenfassung: | <jats:title>Abstract</jats:title><jats:p>While tacrolimus (<jats:styled-content style="fixed-case">FK</jats:styled-content>506) is currently used as immunosuppression therapy in transplant recipient, the immunological mechanism remains unknown. Herein, the immunoregulatory effects of <jats:styled-content style="fixed-case">FK</jats:styled-content>506 were investigated in the physiological status and allogeneic skin transplantation. <jats:styled-content style="fixed-case">FK</jats:styled-content>506 cannot significantly alter the functions of innate immune cells (macrophages and neutrophils) and adaptive immune cells (T cells) in the physiological status. However, it can effectively delay allogeneic skin‐graft rejection through ameliorating the T cell responses, but not myeloid‐derived innate immune cell responses. Importantly, it did not affect the allograft recipient macrophage innate immune defence capacity to bacteria. In clinics, <jats:styled-content style="fixed-case">FK</jats:styled-content>506 treatment can significantly control the cytokine production in T cells, but not non‐T cells. This study shows targeting calcineurin signalling, <jats:styled-content style="fixed-case">FK</jats:styled-content>506, to be essential in inducing allograft tolerance, but not to damage the innate defence capacity, validating the immune cell phenotypes as a potential marker in transplantation following <jats:styled-content style="fixed-case">FK</jats:styled-content>506 treatment.</jats:p> |
|---|---|
| Umfang: | 119-127 |
| ISSN: |
0300-9475
1365-3083 |
| DOI: | 10.1111/sji.12398 |